(Bold for FDA approved)
• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis
• Blocks serotonin 2A receptors, causing enhancement of dopamine release in certain brain regions and thus reducing motor side effects and possibly improving cognitive and affective symptoms
• Interactions at a myriad of other neurotransmitter receptors may contribute to zotepine’s efficacy
• Specifically inhibits norepinephrine uptake
• Psychotic and manic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior as well as on cognition and affective stabilization
• Classically recommended to wait at least 4–6 weeks to determine efficacy of drug, but in practice some patients require up to 16–20 weeks to show a good response, especially on cognitive symptoms
• Atypical antipsychotics may increase the risk for diabetes and dyslipidemia, although the specific risks associated with zotepine are unknown
• Agitation, anxiety, depression, asthenia, headache, insomnia, sedation, hypo/ hyperthermia
• Constipation, dry mouth, dyspepsia, weight gain
• Tachycardia, hypotension, sweating, blurred vision
• Tardive dyskinesia
• Risk of potentially irreversible involuntary dyskinetic movements may increase with cumulative dose and treatment duration
• Dose-related hyperprolactinemia
• Rare neuroleptic malignant syndrome may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability with elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure
• Rare seizures (risk increases with dose, especially over 300 mg/day)
• Blood dyscrasias
• Dose-dependent QTc prolongation
• As a class, antipsychotics are associated with an increased risk of death and cerebrovascular events in elderly patients with dementia; not approved for treatment of dementia-related psychosis
common
common
• Wait
• Wait
• Wait
• For drug-induced parkinsonism, add an anticholinergic agent
• Beta blockers, benzodiazepines, or serotonin 2A antagonists (e.g., mirtazapine, cyproheptadine) may reduce akathisia
• Take more of the dose at bedtime to help reduce daytime sedation
• Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia
• Metformin may help prevent or reverse antipsychotic-induced weight gain
• Reduce the dose
• Switch to a first-line atypical antipsychotic
• 75–300 mg/day in 3 divided doses
• Tablet 25 mg, 50 mg, 100 mg
• Can be used to delay relapse in long-term treatment of schizophrenia
• Should periodically reevaluate long-term usefulness in individual patients, but treatment may need to continue for many years
• No
• Recommended starting dose 25 mg twice a day; recommended maximum dose generally 75 mg twice a day
• Recommended starting dose 25 mg twice a day; recommended maximum dose generally 75 mg twice a day
• May require weekly monitoring of liver function during the first few months of treatment
• Drug should be used with caution
• Zotepine produces a dose-dependent prolongation of QTc interval, which may be enhanced by the existence of bradycardia, hypokalemia, congenital or acquired long QTc interval, which should be evaluated prior to administering zotepine
• Use with caution if treating concomitantly with a medication likely to produce prolonged bradycardia, hypokalemia, slowing of intracardiac conduction, or prolongation of the QTc interval
• Avoid zotepine in patients with a known history of QTc prolongation, recent acute myocardial infarction, and uncompensated heart failure
• Recommended starting dose 25 mg twice a day; recommended maximum dose generally 75 mg twice a day
• Although atypical antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with behavioral symptoms of dementia such as agitation
• Elderly patients with dementia-related psychosis treated with atypical antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events
• Not recommended for use in children under age 18
• Insufficient data in humans to determine risk
• There is a risk of abnormal muscle movements and withdrawal symptomsin newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding
• Zotepine is not recommended during pregnancy
• Zotepine is not recommended during breast feeding
• Immediate postpartum period is a highrisk time for relapse of psychosis, so may consider treatment with another antipsychotic
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera